drugset / Trial / NCT06979453

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453

Phase 3 Recruiting 366 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

Timeline

Start
2025-12-03
Primary completion
2029-10-12
Completion
2034-08-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator CRAVACITINIB Small molecule

Indications